Question Title

* 1. Contact Information

Question Title

* 2. Overall impression of Convention

Question Title

* 3. Registration, Check-in and Assistance

Question Title

* 4. Meeting Rooms

Question Title

* 5. Exhibits

Question Title

* 6. Meals

Question Title

* 7. Hotel Accommodations

Question Title

* 8. Objective #1: Demonstrate in an effective manner procedures for addressing pain crisis in various settings.

Question Title

* 9. Objective #2: Utilize evidence-based guidelines and best practices in their daily care of self and patients to improve patient outcomes and quality of life.

Question Title

* 10. Objective #3: Identify alternate treatment options for the care of themselves and patients. 

Question Title

* 11. Objective #4: Use clinical trials websites to access information regarding participation in various available clinical trials.

Question Title

* 12. Objective #5: Decrease the amount of fragmentation in care from adolescent to adult providers. 

Question Title

* 13. Objective #6: Recognize, identify or assist in the development of social and emotional resources for patients and families. 

Question Title

* 14. Relationship of objectives to overall purpose/goals of activitiy

Question Title

* 15. Wednesday Registration

Question Title

* 16. HRSA Grant Team Meeting

Question Title

* 17. SCDAA Member Training 

Question Title

* 18. Thursday Registration

Question Title

* 19. Thursday Breakfast

Question Title

* 20. Thursday Speed Networking

Question Title

* 21. SCDAA BUSINESS SESSION

Question Title

* 22. Opening Ceremony 

Question Title

* 23. Treatment Demonstration Grant Updates: Rosemary Britt

Question Title

* 24. Newborn Screening Grant Update: Kathy Norcott

Question Title

* 25. PICORI Grant Update: Mary Lamar

Question Title

* 26. Hemolytic Anemia in Sickle Cell Disease: What is it and why Does it Matter? 

Question Title

* 27. Sickle Cell Basics: Wanda Whitten- Shurney, MD

Question Title

* 28. Developing My Healthcare Passport: Andre Harris

Question Title

* 29. Hydroxyurea and Transfusions: Andrew Campbell, MD

Question Title

* 30. Effective Transition: Leila Jerome-Clay, MD, MCTS 

Question Title

* 31. Chronic Organ Damage: Caterina Minniti, MD

Question Title

* 32. Virtual Reality as an Adjunct Pain Management Therapy: Latika Puri, MD 

Question Title

* 33. The Opioid Crisis and Nursing Ramifications: Yvonne Carroll, RN, JD 

Question Title

* 34. The Opioid Crisis- Non Opioid Pain Management Treatment Options: Genice T. Nelson, DNP, APRN,ANP-BC

Question Title

* 35. Telementoring: Sophie Lanzkron, MD, MHS 

Question Title

* 36. Chronic Pain: Deepika Darbari, MD 

Question Title

* 37. Transplantation Update: Courtney Fitzhugh, MD 

Question Title

* 38. Managing Sickle Cell Disease in Older Adults: Swee Lay Thein 

Question Title

* 39. Using Implementation Science to Develop and Evaluate Psychosocial Interventions in SCD: Lori Crosby, PsyD

Question Title

* 40. Examining Spiritual Well Being During Health Care Transition for Adolescents and Emerging Adults with Sickle Cell Disease: Dora Clayton- Jones, RN, PhD, CPNP-PC 

Question Title

* 41. Peer Mentoring vs. Structured Education to Improve Transition to Adult Care in SCD: Ify Osunkwo, MD, MPH 

Question Title

* 42. Community Health Worker vs. A Mobile app to Improve Transition to Adult Care: Kim Smith-Whitley, MD, MPH 

Question Title

* 43. Community Health Worker Training 

Question Title

* 44. PCORI: Lori Crosby, PsyD

Question Title

* 45. Clinical Trail Update 

Question Title

* 46. Dr. Biree Andemariam 

Question Title

* 47. GBT 

Question Title

* 48. Emmaus

Question Title

* 49. Prolong Pharmaceuticals 

Question Title

* 50. Imara

Question Title

* 51. Pfizer

Question Title

* 52. Novartis 

Question Title

* 53. Bluebird bio 

Question Title

* 54. Bioverative 

Question Title

* 55. Ironwood Pharmaceuticals 

Question Title

* 56. Poster Session

Question Title

* 57. Chairman's Reception and Generation S "Rock the Block" Eve Pisces

Question Title

* 58. Friday Registration

Question Title

* 59. Friday Breakfast

Question Title

* 60. Friday Speed Networking

Question Title

* 61. Real Life Experience with Transplantation: Patient and Family perspective: Wanda Whitten Shurney, MD 

Question Title

* 62. Charles F. Whitten, MD Memorial Lecture Dr. Wanda Whitten-Shurney
We've Fallen But We Must Get Up: Dizziness, Falling and Hearing Loss in Individuals Living With Sickle Cell Disease. M. Dawn Nelson, Ph.D. CC-A

Question Title

* 63. Diversity Panel 

Question Title

* 64. Community Health Worker Training 

Question Title

* 65. Healing The Healer Provider Session: Wanda Whitten-Shurney, MD 

Question Title

* 66. Self-Advocacy 101 for Individuals with SCD: Carla Lewis 

Question Title

* 67. Finding your Voice between the Patient and Caregiver: Trudy Tchume- Johnson, LSW, Velvet Brown Watts, MSW, CM 

Question Title

* 68. Lonzie Lee Jones Patient Advocacy Symposium: SCD Hollywood Squares - Celebrating Patient Family Victories

Question Title

* 69. Patient and Caregiver Perspectives on Areas of Burden in Sickle Cell Disease Management: Tilicia Mayo-Gamble, PhD, MPH, MA, CHES

Question Title

* 70. Finding SCD Patients in Michigan- A Case Study: Wanda Whitten-Shurney, MD, Jeanne M. Loboda

Question Title

* 71. The Communication, Awareness, Relationship and Empowerment Model: An Effective Tool for Engaging Urban Communities in Community-Based Participatory Research: Marlene Peters- Lawerence, BSN, RN, RRT

Question Title

* 72. Technology Access and Preferences for Smartphone Application Content Among Adults with Sickle Cell Disease and their Caregivers: Tilicia Mayo-Gamble, PhD, MPH, MA, CHES

Question Title

* 73. Digital Engagement in the Sickle Cell Community: Robin C. Howard 

Question Title

* 74. Novel Ways to Recruit New Health Care Professionals into the Sickle Cell Arena: Donna Pennington Monroe, MS

Question Title

* 75. Geography Seems to be A Factor that Determines the Outcome of Transition for Children with Sickle Cell Disease into Adult Programs: Nina Anderson, RN, DNP

Question Title

* 76. Loneliness Predicts Next-Day Quality of Life in Sickle Cell Disease: A Micro-Longitudinal Analysis: Shawn Bediako, PhD

Question Title

* 77. Discovering and Breaking Down Barriers: Improving Compliance with Appointments in the Pediatric Sickle Cell Clinic: Carla Jones, MSN, RN, Kenneth Mitten, MSW

Question Title

* 78. The Need For Free Sickle Cell Trait Screening Services in America: Gary Gibson

Question Title

* 79. The Opioid Epidemic and CDC Guidelines: A Case of an Unfortunate Consequences Paved  by Good Intentions: Cynthia Sinha, PhD

Question Title

* 80. Availability of Information on Blood Marrow Transplantation (BMT) Coverage Benefits for Patients with Sickle Cell Disease (SCD) Enrolled in Medicaid: Tatenda Mupfudze,  PhD

Question Title

* 81. Stigma Moderates the Association Between SCD Pain Frequency and Emergency Department Utilization: Shawn Bediako, PhD

Question Title

* 82. A Training Approach for Newborn Screening Personnel in Nigeria: Lewis Hsu, MD

Question Title

* 83. The Importance of Social Work in Complex SCD Care: A Model for Clinical Intervention: Teresa Works, MSW, LCSW

Question Title

* 84. The Forgotten Vital Sign: Use of A Distress Thermometer With Children, Adolescents and Young Adults Diagnosed with Sickle Cell Disease: Kenneth Mitten, MSW 

Question Title

* 85. Effect of Long Term Treatment With Sc411 on Sickle Cell Crisis Rate In Children With Sickle Cell Disease: Beng Fuh, MD

Question Title

* 86. Compassionate-Use Voxelotor (GBT440) For up to 2 Years in Patients with Severe Sickle Cell Disease and Life-Threatening Comorbidities: Kenneth R. Bridges, MD 

Question Title

* 87. Crizanlizumab 5.0Mg/Kg Increased the Time to First On-Treatment Sickle Cell Pain Crisis (SCPC) and the likelihood of not expecting experiencing SCPC While On Treatment: Subgroup Analyses of the Phase 2 Sustain Study: Julie Kanter, MD

Question Title

* 88. Parent and Youth Barriers to Hydroxyurea Adherence in Adolescents with Sickle Cell Disease: Arlene Smaldone, PhD, CPNP, CDE

Question Title

* 89. Sickle Cell Patients With Leg Ulcers Have a Pro-Thrombotic Profile: Ugochi Ogu, MD 

Question Title

* 90. Crizanlizaumab Treatment is not Associated With the Development of Proteinuria and Hematuria in Patients with Sickle Cell Disease: Sustain Study Safety Analysis: Julie Kanter, MD

Question Title

* 91. Genome Editing to Fix the Sickle Cell Disease Causing Variant in Sickle Cell Patient Hematopoietic Stem Cells: Matthew Porteus, MD, PhD

Question Title

* 92. Correction of the Sickle Mutation in Hematopoietic Stem/Progenitor Cells with CRISPR/Cas9: The Berkeley/UCSF/UCLA Sickle Cell Clinical Transplantation Project: Mark Dewitt

Question Title

* 93. The Clinical-Stage SGC Stimulator Olinciguat Prevents Increase Of Plasma Biomarkers Of Intravascular Inflammation And Suppresses Leukocyte-Endothelial Interactions In Tnfa-Treated Mice: Boris Tchernychev

Question Title

* 94. Strategies and Next Steps for Improving Sickle Cell Disease Care: Highlights from The Sickle Cell Disease Treatment Demonstration Program

Question Title

* 95. Striving in the Workforce with Sickle Cell: Terri Booker, Esq. & Carla Lewis

Question Title

* 96. Red Carpet Reception Featuring Red Carpet Interviews

Question Title

* 97. UNITY SOIREE

T